Anygen Co., Ltd. (KOSDAQ:196300)

Market Cap	54.63B
Revenue (ttm)	6.12B
Net Income (ttm)	-8.67B
Shares Out	6.00M
EPS (ttm)	-1,452.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	281,607
Average Volume	552,502
Open	10,700
Previous Close	10,530
Day's Range	10,110 - 11,010
52-Week Range	5,580 - 17,450
Beta	0.63
RSI	46.88
Earnings Date	n/a

About Anygen

Anygen Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It develops GMP, generic, custom, and catalog peptides, as well as offers other services. The company is also developing AGM-331 targeted for anti-cancer therapy, currently under pre-clinical development phase; AGM-130 indicated for the treatment of triple negative breast cancer, currently under Phase I development phase; AGM-380 indicated for the treatment of viral infection, currently ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 196300

Financial Performance

In 2023, Anygen's revenue was 5.61 billion, a decrease of -35.23% compared to the previous year's 8.66 billion. Losses were -9.08 billion, 46.3% more than in 2022.